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MECHANISM OF HYPERTHROMBOTIC CANCER MILIEU 
DANIEL ROTH 
ABSTRACT 
 Cancer and thrombosis are common co-occurrences in healthcare today. Cancer is 
the second leading cause of death in the United States with thrombosis being the second 
leading killer of cancer patients behind tumor progression. Cancer patients as a whole are 
4 to 7 times more likely to develop thrombosis and 20%-30% of all first-time thrombosis 
diagnoses are cancer-related. Risk assessment and treatment options have much room for 
improvement. The lack of success for conventional antithrombotic prophylaxis suggests 
that hyperthrombosis in cancer works through a discrete pathway.  
A discovery by our group in recent years correlated the increased activity of Aryl 
hydrocarbon receptor (AHR) in the body to increase thrombotic phenotypes in patients 
with chronic kidney disease. Another group had published a manuscript about 
Kynurenine (Kyn), an activating ligand of the receptor that was produced by tumor cells 
to promote tumor growth through an AHR pathway (Opitz 2011). The link between the 
findings of these two groups could show that Kyn—AHR pathway is causing the increase 
in thrombosis in cancer patients. We used an animal model of thrombosis in cancer and 
created a new variation of it to test the Kyn—AHR pathway. We hypothesized that 
cancerous animals would show an increase in thrombosis and increased levels of AHR 
and Kyn along with downstream elements such as Tissue Factor (TF).  
Cancer was induced on nude mice via xenograft injection of cancer cells and 4-5 
weeks of incubation to allow the tumors to proliferate. After the incubation period, mice 
	
	 vii 
underwent inferior vena cava (IVC) ligation, and were then euthanized 48 hours later. 
Two types of cancer were tested: HT-29 colon adenocarcinoma and A549 non small cell 
lung adenocarcinoma. There were 4 animal groups: mice that were injected with cancer 
cells and operated on, mice that were injected with cancer cells but not operated on, mice 
that were not injected but were operated on, and mice that did not receive neither the 
injections or the operation. After euthanasia, blood, tumors, and major organs were 
harvested to assess markers and pathways of thrombosis associated with cancer. 
We were able to successfully grow xenograft tumors in the nude mice. The HT-29 
tumors grew very aggressively while A549 tumors experienced a small latent period 
before starting to proliferate. Animals with HT-29 and A549 xenograft tumors displayed 
greater thrombosis, measured by the weight of the blood clot formed in the IVC due to 
ligation (p=0.04 and p=0.05, respectively). HT-29 also displayed significant increases in 
Kyn, AHR activity, indoxyl sulfate (IS), and showed increased staining of tissue factor 
with immunohistochemistry. A549 did not have significant p-values in these experiments, 
but did show upward trends in all categories besides IS sera levels. 
In summary, we developed a new animal model of thrombosis in colon 
adenocarcinoma and showed significant increases in thrombosis as well as multiple 
markers of thrombosis. This is an exciting and complex way to study thrombosis in 












TABLE OF CONTENTS ................................................................................................. viii	
LIST OF TABLES ............................................................................................................. xi	
LIST OF FIGURES .......................................................................................................... xii	
LIST OF ABBREVIATIONS .......................................................................................... xiii	
INTRODUCTION .............................................................................................................. 1	
CLINICAL RELEVANCE ............................................................................................. 1	
TREATMENT AND RISK ASSESSMENT .................................................................. 3	
THE COAGULATION CASCADE ............................................................................... 4	
MOLECULAR FINGERPRINT OF CANCER-ASSOCIATED THROMBOSIS ........ 4	
TISSUE FACTOR ...................................................................................................... 6	
ARYL HYDROCARBON RECEPTOR .................................................................... 6	




MOUSE MODELS OF THROMBOSIS AND VTE ...................................................... 8	
ANIMAL MODELS OF CANCER .............................................................................. 10	
SPECIFIC AIMS .......................................................................................................... 13	
METHODS ....................................................................................................................... 16	
ANIMAL MODEL ....................................................................................................... 16	
IVC LIGATION ............................................................................................................ 17	
TISSUE HARVEST ..................................................................................................... 18	
LUCIFERASE ASSAY ................................................................................................ 18	
TISSUE FIXATION AND PROCESSING .................................................................. 19	
IMMUNOHISTOCHEMISTRY .................................................................................. 20	
H&E STAINING .......................................................................................................... 21	
RESULTS ......................................................................................................................... 22	
TUMOR GROWTH ...................................................................................................... 22	
THROMBUS WEIGHT ................................................................................................ 22	
IMMUNOHISTOCHEMISTRY OF XENOGRAFT TUMOR .................................... 25	
MASS SPECTROMETRY OF MOUSE SERA ........................................................... 28	
AHR LUCIFERASE ASSAY ....................................................................................... 29	











LIST OF TABLES 
 
 
Table Title Page 
1 Incidence of Venous Thrombosis per Malignancy Within 
5 Years of Diagnosis. 
 
5 
2 Mouse Models of Thrombosis. 11 
   
   
   









Figure Title Page 
1 Tumor-Secreted Metabolites Increase Thrombogenicity. 14 




3 Xenograft Tumor Growth in Nude Mice. 23 
4 Mean Weight of IVC Clot. 24 




6 Immunohistochemistry of Xenograft Tumors with AHR. 
 
26 
7 Immunohistochemistry of Xenograft Tumors with IDO. 27 
8 Immunohistochemistry of Xenograft Tumors with TF. 27 
9 Mass Spectrometry of Nude Mouse Serum. 28 
10 AHR Activity Luciferase Assay. 29 




LIST OF ABBREVIATIONS 
 
AHR ............................................................................................ Aryl hydrocarbon receptor 
DVT ................................................................................................... Deep vein thrombosis 
FVII ....................................................................................................................... Factor VII 
FVIIa ..................................................................................................... Activated factor VII 
GEM ......................................................................................... Genetically engineered mice 
HSP90 ................................................................................................ Heat shock protein 90 
IDO ........................................................................ Indoleamine 2,3-dipyrrole deoxygenase 
IS ................................................................................................................... Indoxyl sulfate 
IVC ........................................................................................................... Inferior vena cava 
Kyn ...................................................................................................................... Kynurenine 
L ............................................................................................................... Length (long axis) 
NSCLC ................................................................................. Non small cell lung carcinoma 
O.C.T........................................................................................ Optimal cutting temperature 
PE ........................................................................................................Pulmonary Embolism 
RPMI ................................................................................. Roswell Park Memorial Institute 
TBST ............................................................................. Tris buffered saline with Tween-20 
TF ..................................................................................................................... Tissue Factor 
V ................................................................................................................................ Volume 
VTE ............................................................................................. Venous thromboembolism 
W .............................................................................................................. Width (short axis) 





Cancer and thrombosis have a well-known association. They were first 
recognized together almost 200 years ago by Bouillard in 1823, and were then first 
correlated by Armand Trousseau in 1865, who then died of the very thing 2 years later 
(Bouillard 1823, Trousseau 1865, Timp 2013). Lately, there have been more large-scale 
clinical studies and many research groups studying these coinciding pathological 
phenomena. These more recent studies are finding that this issue is more prevalent than 
previously thought. They show that the risk of thrombosis is significantly elevated in 
patients with cancer, especially during the first months after diagnosis and in cases of 
metastatic cancer (Blom 2005). Additionally, those diagnosed with a first episode of 
thrombosis also have a higher risk of having their first diagnosis of cancer within 2 years 
(Murchison 2004). This two-way association shows a strong relationship and still 
requires much more research. 
 
Clinical Relevance  
Clinically, thrombosis poses a great risk to embolize. From the leg where most 
thrombi form, embolisms can travel through the body to organs like the lungs and brain. 
It is consistently estimated that roughly 20%-30% of all first cases of venous 
thromboembolism (VTE) are associated with cancer across all ages and both sexes (Timp 
2013). Patients that were diagnosed with any malignancy over the previous 15 years were 
nearly 7 times more likely to have a VTE than the controls (Blom 2005). The same study 
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found that certain malignancies had a 28-fold risk of developing VTE. Table 1 from 
Blom et. al shows differential frequency of thrombosis from different malignancies. 
Cancer is the second leading cause of death in the United States (Siegel 2018), and 
among cancer patients the second leading cause of death is VTE. 14% of the deaths of 
hospitalized cancer patients die of pulmonary embolism (PE), one of two types of VTE—
the other being deep vein thrombosis (DVT). Regardless of the outcome of VTE, cancer 
patients that develop a thrombus have a worse prognosis than those that don’t regardless 
of whether their death is directly caused by thrombosis or not (Khorana 2010). In any 
event, the diagnosis of VTE is life changing and requires many lifestyle changes as well 
as a new medical regiment for those affected. 
 The diagnoses of thrombi and thromboembolisms are also difficult to detect. 
Sweet et. al found in 2013 that only 32% of diagnoses of PE are made ante mortem, 
which is actually a large improvement from under 8% in the early 1980s (Sweet 2013). 
This statistic is worrisome for a thromboembolic event that has been estimated to kill 1% 
of all hospital admissions and is responsible for 10% of all hospital deaths (Lankeit 
2011).  
The mean cost of an admission for PE is $9,566 and that figure increases to 
$12,200 for the dual diagnosis of PE and DVT (Fernandez 2015). Given that the 
occurrence of VTE is between 1 and 2 per 1000 in the United States (Beckman 2010), the 
total cost of VTE is over $3 billion, conservatively. Since 20%-30% of all VTE are 





Treatment and Risk Assessment 
The traditional treatment for patients that are susceptible to thrombosis is 
anticoagulant medication. The benefits of these drugs are significant for 
thromboprophylaxis, but must be used in only high-risk patients because of their side 
effects. There is evidence that low molecular weight heparin has been beneficial for 
cancer patients in reducing thrombotic events (Mahé 2018), but incidence of bleeding in 
patients receiving anticoagulant therapy was significantly higher in patients who also had 
cancer (Palareti 2000). Cancer’s complexity allows it to increase patients’ risk of 
thrombosis, but it also increase risk of bleeding events. Some cancer patients would have 
better prognoses with stronger anticoagulants (Prandoni 2002) and some would have 
done better without them at all. This is an area of ongoing interest and requires much 
further elucidation into how to prescribe the right treatment for patients with cancer, as 
well as a need for new innovations in the treatment of thrombosis. 
 Assessing the risk of thrombosis in cancer patients can also be difficult. The 
Khorana Scale is the most commonly used scale for measuring risk of thrombosis (Yust-
Katz 2015), but is not without criticism. In a Delphi method study, a cohort of experts on 
thrombosis agreed to a majority that the Khorana scale is insufficient in classifying risk 
stratification in individual patients (Jimenez-Fonseca 2017). With the eventual discovery 
of new biomarkers of thrombosis in cancer, clinicians will be more capable of assessing 
risk and preventing complications associated with anticoagulant therapy when its use in 
not indicated.  
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The Coagulation Cascade 
The three primary causes for thrombus formation are known as Virchow’s triad: 
stasis, endothelial or vessel wall injury, and hypercoagulability. The coagulation cascade 
is an extensive, multifactorial network of pathways that involves all of the cellular and 
non-cellular components of blood and the surrounding vasculature as well. The extrinsic 
pathway of blood coagulation is activated when Tissue Factor (TF) from subendothelial 
tissue is exposed to the circulating Factor VII (FVII), binding to it and converting it to 
activated FVII (FVIIa). The TF/FVIIa complex binds and activates Factor X, which 
cleaves prothrombin to thrombin. Thrombin promotes platelet aggregation and activation, 
and causes the formation of a platelet plug, the preliminary product of blood coagulation. 
The TF/FVIIa complex is a necessary component of this side of the coagulation cascade 
(Mackman 2009). Overexpression of TF in cancer causes hypercoagulability and is 
viewed as a major contributor to the increased incidence of VTE in cancer patients. 
 
Molecular Fingerprint of Cancer-Associated Thrombosis  
 In the wide range of proteins that are overexpressed by cancer, our group aims to 
identify and probe for some of these proteins that have activating effects on TF. In this 
set of experiments, aryl hydrocarbon receptor (AHR), indoleamine 2,3-pyrrole 





Table 1 Incidence of Venous Thrombosis per Malignancy Within 5 Years of 
Diagnosis. A study by Blom et. al in 2005 identified 4,300 patients with a first venous 







TF plays important roles in both coagulation and angiogenesis. The 
overexpression of TF is critical for the growth of new microvasculature, which makes it a 
hallmark of all neoplastic growth. Any tumor over 2mm3 in volume will need to instigate 
angiogenesis to recruit its own blood supply (Arderiu 2014). Cancer has abnormal and 
often upregulated expression of many different proteins. Its need for recruitment for its 
own blood supply causes increased levels of TF locally, and also TF production by cells 
that normally do not produce it (Bluff 2008). In physiologic conditions, only 
subendothelial cells constitutively express tissue factor (Ueno 2000). In patients with 
cancer, much of that regulation is lost and tissue factor is found in monocytes, endothelial 
cells, and also circulating in the blood (Bluff 2008). The presence of tissue factor in the 
blood causes constitutive activation of the extrinsic pathway of blood coagulation and can 
contribute to the hypercoagulability of cancer patients. 
Aryl Hydrocarbon Receptor 
AHR is a cytoplasmic protein that has prominent roles in serving as a mediator for 
toxins in the body and in the immune response to inflammation and tumorigenesis (Opitz 
2011). AHR is a transcription factor that is bound to heat-shock protein 90 (HSP90) at its 
DNA binding domain in the cytoplasm when inactive. When activated by either its 
endogenous ligands or by exogenous toxins, AHR translocates to the nucleus and 
dissociates from HSP90 by the actions of AHR nuclear translocator protein (Stockinger 
2014). Among the genes activated by AHR are those that encode Cytochrome p450 
proteins, which reduce reactive oxygen species in the body (Israel 1983). 
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Increased AHR levels are correlated with hyperthrombotic phenotypes as it 
interacts directly with TF to stabilize and increase TF levels. Addition of antagonists for 
the AHR in vitro led to its ubiquitination and degradation as well as a drop in TF levels 
(Shivanna 2016). Increased levels of indoxyl sulfate, an agonist of AHR, increased TF 
levels and led to increased thrombogenicity (Opitz 2011). 
Indoleamine 2,3-dioxygenase 
Indoleamine-pyrrole 2,3-dioxygenase (IDO) is one of three enzymes responsible 
for the rate-limiting step of the Kynurenine—AHR pathway. The purpose of this pathway 
is the catabolism of tryptophan, which has been shown to slow antitumor immune 
responses and also T cell proliferation (Muller 2005). Kynurenine (Kyn), a metabolite of 
tryptophan, is an endogenous agonist of AHR that is highly expressed by tumors. Kyn 
has been shown to stimulate tumor growth in the absence of other AHR ligands (Opitz 
2011).  
Inhibitors of IDO have been shown to greatly slow tumor growth and improve 
chemotherapy and other cancer treatments’ effectiveness (Prendergast 2018). In many 
cancers IDO is highly activated in order to remove tryptophan from its local environment 
and suppress immune function (Munn 2007), and also to indirectly increase tissue factor 
activity through AHR. 
β-Catenin  
β-catenin is a multifunctional cytoplasmic protein that is involved in both cell-to-
cell adhesion and gene transcription (Clevers 2006). Overexpression of beta-catenin 
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within the Wnt/β-catenin pathway can lead to cancers; amongst those are colorectal 
cancer and lung cancer (Lee 2018, Wang 2017, Wang 2018). β-catenin is recruited, and 
its destruction is inhibited by the activation of the canonical Wnt pathway 
(Krishnamurthy 2017).  
The pathway starts at the cell membrane with Wnt binding the Frizzled/LRP 
coreceptor complex. This phosphorylates the protein Dishevelled, which goes on to 
phosphorylate Glycogen Synthase Kinase 3 and release Beta-catenin from its Axin 
degradation complex via dephosphorylation of β-catenin (Gammons 2018). Activating 
mutations of the CTNNB1 gene that codes for β-catenin are rare and were found in just 
two of 92 colorectal cancer patients in one study (Kiteava 1997) Its increase most 
commonly stems from a diminished or non-functioning mutated Adenomatous polyposis 
coli protein of the Axin destruction complex, which is found to be abnormal in 85% of 
colon cancers (Kiteava 1997).  
While this pathway has many different downstream targets and effects on the cell, 
a common function of the Wnt/β-catenin pathway is to specify and control differentiation 
of stem and progenitor cells (Nusse 2017). This feature of the Wnt/β-catenin pathway 
could explain why many cancers feature mutations within this pathway, and why it’s also 
a very indicative marker of cancer. 
 
Mouse Models of Thrombosis and VTE 
Finding a translational and replicable model of human thrombosis in animals was 
very important in these experiments. Since humans are the only species capable of 
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developing spontaneous deep vein thrombosis, there must be surgical intervention to 
incur thrombosis in animals (Albadawl 2017). For these experiments, mice were used. 
There are many common models of human thrombosis in mice that all have unique 
characteristics.  
For models of thrombosis involving small vessels, there is the mechanical injury 
model (Pierangeli 1994), the endothelial stimulation via mutated von Willebrand factor 
model (André 2000, Brill 2011), or the electric injury model (Carmeliet 1997). Small 
vein models are helpful for studying acute thrombosis, but cannot accommodate a vessel 
as large as the IVC nor are they useful for chronic thrombosis (Diaz 2012). 
Large vein models include the ferric chloride model, the photochemical injury 
model, the IVC ligation model, the IVC stenosis model, and the electrolytic vein model. 
The ferric chloride model involves placing a small strip of filter paper that has been 
soaked in a ferric chloride solution ranging from 5% to 20% FeCl3 placed on the blood 
vessel for 1 to 2 minutes (Misra 2018, Diaz 2012). The photochemical injury model uses 
intravenous Rose Bengal injections followed by exposing a vessel and directing a green 
laser towards it from 5cm-6cm away (Eitzman 2000). The reaction between the light and 
the Rose Bengal create oxidative species that damage the endothelial wall and cause 
thrombosis. The IVC ligation model is an invasive surgical model that involves careful 
externalization of the intestines to expose the retroperitoneal IVC. From there, a non-
reactive suture is used to completely ligate the vessel (Lee 2015). The IVC stenosis 
model is a similar procedure to the IVC ligation model other than the degree of occlusion. 
In the IVC stenosis model, a 30G needle is placed between the suture and the IVC, and is 
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then removed after the suture has been tied around the vessel and the needle (Payne 
2017). The electrolytic IVC model uses electric current to stimulate thrombogenesis. This 
model is also identical to the others at the start as a midline laparotomy is performed 
followed by intestinal externalization. To stimulate thrombosis, either a needle or a small 
wire threaded through a needle is inserted into the IVC and a small direct current (250 
µAmps) is applied for 15 minutes. This serves to activate endothelial cells by forming 
reactive oxygen species (Diaz 2013). Table 2 highlights the common uses and advantages 
and disadvantages of these different large vessel models. 
 
Animal Models of Cancer 
 The laboratory mouse, or Mus musculus, is one of the best animals to use as a 
model of human biology. It is very similar molecularly and physiologically to humans, is 
small and relatively inexpensive to maintain, and is very easy to breed (Frese 2007). 
Models of cancer include xenograft “animal culture” models, environmentally induced 
models, and genetically engineered mice (GEM), which is broken down into transgenic 
GEM and endogenous GEM (Frese 2007). Xenograft models were one of the first cancer 
models and laid the foundation for much of the progress in animal cancer model research. 
It is done by injecting human cancer cell lines into immune- deficient mice that will be 
unable to reject the foreign cells. Environmentally induced models involve exposing mice 
to radiation, chemicals, or certain viruses or microbes. Transgenic mouse models of 
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Table 2 Mouse Models of Thrombosis. A comparative table contains the methodology, 







targeting and transduction in embryonic stem cells. Lastly, Endogenous GEM is 
accomplished by creating a gene knockout of a tumor suppressor gene or altering the 
expression of endogenous oncogenes. The different models all have limitations and can 
each be insightful for different applications. 
 The xenograft model has the advantage of being a more accessible and reliable 
model of cancer as well as being able to observe the progression of human cancer or even 
patient-specific tumors (Hidalgo 2014). Researchers can be sure of the cell type that will 
incubate inside the immunocompromised mouse and will form a tumor. This model lacks 
some other crucial features of the tumor microenvironment such as stromal cells, 
invading immune cells, and nearby normal tissues (Becher 2006). Others also point to the 
cell culture environment the cells are raised in before xenograft injection. In cell culture, 
the cell line can undergo selective processes in which the polyclonal nature of cancer is 
lost (Kang 2003).  
 Environmentally induced cancer models in mice are most useful in identifying 
oncogenes and tumor suppressor genes. The more autonomous onset of cancer makes this 
a more clinically relevant model for research as well (Frese 2007). Its downsides include 
the limited subset of tumors that arise as a result from the environmental carcinogens that 
the mice are exposed to. There is also significant variance and a relatively long latency 
period for cancer to present (Kripke 1977). 
 Transgenic cancer models are currently the most highly regarded mouse cancer 
models. They are most closely able to simulate human cancer, but also have their limits. 
By allowing the mice to develop cancer through mutating endogenous oncogenes or 
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tumor suppressor genes, mice develop tumors that are predominantly of mesenchymal 
origin instead of carcinomas, which are more common in humans (Frese 2007).  There is 
also troubleshooting involved as unwanted side effects or difficulties with breeding can 
occur in gene modification that will confound results. Time and money are also 
disadvantages of this model, as well as the direct transduction model. The US National 
Institutes of Health estimated that it takes the typical lab about one year and costs 
between $100,000 and $200,000 to create a transgenic mouse model (Rusk 2007). 
Certainly, all advantages and disadvantages of each cancer model must be taken into 
account before starting an experiment. 
 
Specific Aims 
 Our group, collaborating with Dr. Ravid and her laboratory, identified and 
published a paper detailing novel leads to thrombotic regulators (Shashar 2017, 
Abbonante 2017). The potential regulators of thrombosis were metabolites of tryptophan 
including Kyn and a group of indolic solutes, which activated the Aryl Hydrocarbon 
(AHR) Receptor pathway. An independent group had found that the AHR pathway was 
activated by an endogenous ligand produced in tumors (Opitz, 2011).  
 Our goal was to develop a mouse model of venous thrombosis in cancer that 
closely simulates the venous thrombosis of human cancer patients. The types of cancer 
were specifically chosen for the increased risk of thrombosis associated with them. With 
the model, we probed mouse tumors, blood, and vasculature so that we could further 
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investigate the Kyn—AHR pathway. We will then correlate levels of these potential 
thrombosis mediators with the thrombogenicity of the animal. 
 We hypothesize that there would be increased levels of metabolites and ligands in 
the Kyn—AHR pathway of the experimental animals against control animals, which 
would lead to a subsequent increase in TF. We also expected to find increased 
thrombogenicity in the cancerous mice over the control mice. 
 
Figure 1 Tumor-Secreted Metabolites Increase Thrombogenicity. Tumors secrete 
Kyn among other tryptophan metabolites that increase AHR,. In chronic kidney disease, 
AHR has proven to increase TF expression and its antagonists decrease TF (Shivanna 
2016).  
	 


























































Figure 2 Experimental Overview of the Animal Model and Harvest. Mice are either 
implanted with a xenograft injection or are used as controls. After the tumor incubation 
period, the mouse undergoes inferior vena cava ligation. 48 hours later, the mouse is 
euthanized and the thrombus that formed in the inferior vena cava is weighed and tissues 
are harvested. Figure created conjointly with Dr. Belghasem.  
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All experiments were approved by the Institutional Animal Care and Use 
Committee. Animals were cared for in compliance with the Boston University 
Institutional Animal Care and Use Committee and in accordance with the “Principles of 
Laboratory Animal Care‟ formulated by the National Society for Medical Research and 
the “Guide for the Care and Use of Laboratory Animals, 8th edition‟ (NIH 2011). 
 
Animal Model  
Mice from Jackson Laboratory (Bar Harbor, ME) were used for the experiments. 
The strain used was strain 002019 athymic nude mice. The mice were fed a normal diet 
and water ad libitum.  
The 2 different cell lines were plated at 106 cells per plate and grown in Roswell 
Park Memorial Institute (RPMI) medium (Gibco Laboratories, Gaithersburg, MD) with 
10% Fetal Bovine Serum and 1% Penicillin Streptomycin in 10cm dishes. The cells were 
harvested at 80% confluency with tripsin, placed in a centrifuge at 302g for 5 minutes. 
The supernatant was aspirated and the pellet was re-suspended in a 1:1 mixture of serum-
free media and Matrigel (Corning Inc. Tewksbury, MA). The mice were injected with 
3×106 cells in 200µL of cell suspension. 
The mice received A549 non-small cell lung cancer cells (NSCLC) and HT-29 
colon adenocarcinoma cells. All injections of cells were done with a 23-guage needle to 
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avoid cell lysis. The cells were injected as xenograft tumors subcutaneously on the back. 
The mice were carefully monitored for tumor growth over the next 3 weeks.  
Tumors were measured for growth using a caliper (VWR, Radnor, PA). The 
tumors were measured on their longest axis (L), and the axis perpendicular to the long 




After the incubation times for each cell line, the mice underwent inferior vena 
cava ligation as well as ligation of the left gonadal vein and other nearby tributaries. 
Under isoflurane anesthesia, our surgeon performed a midline laparotomy and gentle 
externalization of the intestines to expose the major abdominal vessels. A wire retractor 
was placed to hold the surgical field open. The bowels were placed inside sterile gauze 
that was soaked in isotonic saline to prevent drying. A heating pad was also placed under 
the surgical field to prevent hypothermia during the operation. The abdominal aorta and 
IVC were separated by blunt dissection with fine forceps under a surgical microscope. A 
length of 7-0 nylon suture was threaded between the vessels to ligate the IVC. The 
ligation occurred just inferior to the anastomosis of the renal vein and the IVC to allow 
drainage from the kidneys. The left gonadal vein was also ligated in a similar manner, 
which would otherwise provide collateral flow for the inferior vena cava. Due to 
anatomical variation, up to 4 tributaries in addition to the inferior vena cava were ligated 
in the mice. It should be noted that there were also small tributaries posterior to the vena 
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cava that may have provided collateral flow, but could not be safely reached surgically. 
Venous occlusion via monopolar cautery was considered, but not used. After replacement 
of the bowels, the wound was closed with 4-0 polyglycolic acid suture for the muscle 
layer and surgical skin staples. 
For experimental controls, there were mice that received sham injections. Those 
mice still underwent inferior vena cava occlusion. There were also surgical sham mice as 
well to control for any coagulopathy caused by surgical trauma. Last, there were mice 
that were completely untreated to be used as controls.  
 
Tissue Harvest 
Blood was collected from left common carotid artery, pipetted into 1.5 mL tubes 
containing 4µL of heparin and placed into a centrifuge at 2000g for 30 minutes to 
separate the blood components and aspirate the plasma from the blood. The plasma was 
stored at -80°C until being sent to the Metabolomics Center at the University of Missouri 
for mass spectrometry. Organs and tumors were collected and immediately placed into 
formalin or embedded and frozen in Embedding medium for frozen tissue specimens to 
ensure optimal cutting temperature (O.C.T.) for histological experiments.  
 
Luciferase Assay 
 All buffers and reagents were purchased and prepared from the Dual Luciferase 
Reporter Assay from Promega (Madison, WI). Endothelial cells that express the 
luciferase sequence on the xenobiotic response element (XRE), the classical response 
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motif to AHR signaling, were treated with media containing sera from the cancerous 
mice as well as control mice for 24 hours before the start of the experiment. If the serum 
activates AHR, there will be transcription of XRE and that will cause luminescence under 
a plate reader.  
For the assay, media was removed and the plates were rinsed twice with PBS. The 
PBS was then removed and Passive Lysis Buffer was added and left for 15 minutes at 
room temperature on a rocker. Afterwards, the cell lysate was pipetted several times to 
ensure a homogeneous solution and then 40µL cell lysate was pipetted into a 96 well 
plate. The plate containing the lysates was then frozen at -80° C.  
The plate was removed from the freezer and placed on an orbital shaker to thaw 
for 30 minutes at room temperature. Following thawing, 20µL of Luciferase Assay 
Buffer II was added to wells in rapid succession before placing the plate into the plate 
reader.  
 
Tissue Fixation and Processing 
The formalin-fixed tissue was processed with increasing gradations of ethanol and 
then xylene before infiltration with paraffin. The specimens were then paraffin embedded 
and sectioned at a thickness of 4µm. The slides were baked at 60°C for 45 minutes and 





The slides were deparaffinized and rehydrated by placing in xylene twice for 5 
minutes followed by two 3-minute washes in 100% ethanol, and then 2 washes for 2 
minutes each in 95% ethanol and then again in 70% ethanol. The slides were then placed 
in deionized water before being placed in warm 10mM trisodium citrate solution with 
0.05% Tween 20 buffered to pH 6.0. The slides were heated in the buffer in a microwave 
at 95°C for 20 minutes. Then the slides were left in the hot buffer at room temperature for 
45 minutes to cool down and complete the antigen retrieval phase.   
The tissue was surrounded with a Super-Pap Pen hydrophobic barrier and was 
permeabilized in a solution of 0.3% Triton X-100 in 1x PBS for 10 minutes. The slides 
were washed twice in TBS with 0.05% Tween-20 (TBST). Using solutions from the 
EXPOSE Mouse/Rabbit Specific HRP/DAB Kit (Abcam 80436) (Cambridge, MA), 
hydrogen peroxide block was added for 10 minutes. Slides were then washed twice in 
TBST before adding a serum-free protein block for 30 minutes. The protein block was 
removed and primary antibodies diluted in protein block were applied overnight at 4 
degrees.  
The next day, the slides were washed twice in TBST. Mouse specifying conjugate 
was added for anti-mouse antibodies for 10 minutes, and then washed off twice with 
TBST. The slides were incubated for 15 minutes at room temperature with goat anti-
rabbit HRP conjugate secondary antibody. Slides were washed twice in TBST and then 
administered DAB chromogen-substrate solution to stain. The reaction was closely 
monitored under light microscopy for the DAB reaction to occur. The slides were placed 
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in water to stop the reaction. Then the slides were counterstained in Harris Modified 
Hematoxylin (Fisher Scientific, Fair Lawn, NJ) for 8 seconds, washed in water, and 
dehydrated in increasing concentrations of ethanol and xylene. The slides were mounted 
using Vectamount (Vector Laboratories, Burlingame, CA) and a coverslip.  
The antibodies used were mouse monoclonal Aryl hydrocarbon receptor (1:50) 
(Invitrogen MA1-514 Waltham, MA), rabbit polyclonal β-Catenin (1:50) (Santa Cruz 
Biotechnology sc-7199 Dallas, Texas), mouse monoclonal indoleamine 2,3-dioxygenase 
(IDO) (1:50) (Millipore MABF850 Etobicoke, Ontario), and rabbit polyclonal Tissue 
Factor (1:50) (Abcam 104513 Cambridge, MA).  
 
H&E Staining 
 Hematoxylin and Eosin staining was done on 4µm paraffin-embedded slides by 








 The different cancer cell lines showed different growth rates (Figure 3). The A549 
NSCLC (Figure 3A) grew to an average of 588mm3 over the course of 4 weeks, while the 
HT-29 colon adenocarcinoma grew to an average of 4,226mm3. The A549 cells appeared 
to have a quiescent period of 2 to 3 weeks before starting to proliferate. The HT-29 cells 
(Figure 3B) had begun to grow steadily by 1 week post-injection and continued 
throughout the experiment. 
	
Thrombus Weight 
 The thrombi extracted from the inferior vena cava of the mice were immediately 
weighed. Some mice did not develop thrombi, and were recorded as having a thrombus 
weight of 0mg. The thrombogenicity of both the colon adenocarcinoma and the NSCLC 









Figure 3 Xenograft Tumor Growth in Nude Mice.  (A) A549 NSCLC and (B) HT-29 
Colon adenocarcinoma cells were injected at time 0 weeks and were measured over the 














































Figure 4 Mean Weight of IVC Clot. The clot was extracted from the mouse and 
separated from the IVC. The average clot weight was significantly elevated in both 
(NSCLC) and in the colon adenocarcinoma (HT-29 CRC model) compared to the control 






Immunohistochemistry of Xenograft Tumor 
 The different cell lines were probed for various markers of both cancer and 
thrombosis. The first is β-catenin, a key regulator of cell proliferation and a hallmark for 
a host of cancers. Figure 5 shows the different subcellular areas of β-catenin expression 
within the xenograft tumors. AHR (Figure 6) was also highly expressed in the tumors. Its 
expression was most prominent in the cytoplasm and the nuclei of cells. IDO (Figure 7) 
was expressed almost exclusively in the vasculature of the tumors. TF (Figure 8) had 
mostly cytoplasmic expression with some distinct granules within the cytoplasm. Each 




Figure 5 Immunohistochemistry of Xenograft Tumors with β-catenin. The control 
(A) did not show any background staining. A549 NSCLC (B) paraffin sections showed 
positive β-catenin staining on the membrane and in the nucleus and cytoplasm. Colon 
adenocarcinoma showed positive staining at the membrane, cytoplasm, and nucleus as 




Figure 6 Immunohistochemistry of Xenograft Tumors with AHR. The control (A) did 
not show any background staining. A549 NSCLC (B) showed predominantly nuclear 
staining (*) with also significant staining of the cytoplasm (†). HT-29 Colon 
adenocarcinoma (C) showed more cytoplasmic staining than nuclear staining. 
* 
AHR 
A C B 
50 µm 50 µm 50 µm HT-29 A549 CTL 
50 µm 50 µm 50 µm HT-29 A549 CTL 
β-Catenin  







Figure 7 Immunohistochemistry of Xenograft Tumors with IDO. The control (A) did 
not show any background staining. For both A549 NSCLC (B) and for HT-29 colon 
adenocarcinoma (C) cell lines, IDO stained exclusively on the endothelium. Within the 
endothelium, IDO stained in the cytoplasm mostly, but some stained endothelial cell 




Figure 8 Immunohistochemistry of Xenograft Tumors with TF. The control (A) did 
not show any background staining. A549 NSCLC (B) showed cytoplasmic staining. HT-
29 Colon adenocarcinoma (C) also had cytoplasmic staining, but also showed small 
granules of more intense staining. 
IDO 
A C B 
50 µm 50 µm 50 µm HT-29 A549 CTL 
TF 
A C B 





Mass Spectrometry of Mouse Sera 
  Mass spectrometry of mouse sera obtained from mice with xenograft tumors was 
analyzed for Kyn and indoxyl sulfate (IS). Kyn levels were significantly elevated in the 
HT-29 colon adenocarcinoma compared to the nude control mice (p=0.03) and the A549 
NSCLC showed a trend towards significance for elevated Kyn levels (p=0.06) (Figure 
9A). For indoxyl sulfate (Figure 9B), the colon adenocarcinoma again showed a 
significant increase in blood levels (p=0.01), but there was not an appreciable increase in 
the IS levels of NSCLC (p=0.7). 
 
Figure 9 Mass Spectrometry of Nude Mouse Serum. (A) Kynurenine levels in nude 
mice with HT-29 colon adenocarcinoma (HT-29 CRC model) were higher than that of 
control nude mice (p=0.03). Kyn levels in NSCLC were elevated but were not significant 
(p=0.06). (B) Indoxyl sulfate levels in HT-29 CRC model were significantly elevated 








AHR Luciferase Assay 
 Upon treatment with sera from mice with HT-29 colon adenocarcinoma and A549 
NSCLC, endothelial cells containing the luciferase sequence in their XRE motif showed 
increase luminescence compared to cells treated with sera from control mice. The 
increased luminescence is indicative of increased AHR activity. Both the colon and 
NSCLC showed an increase in luminescence, but only the increased luminescence in 
colon adenocarcinoma was significant. 
 
Figure 10 AHR Activity Luciferase Assay. Sera from mice with HT-29 colon 
adenocarcinoma xenograft tumors showed a significant increase in AHR activity 


















































Immunohistochemistry of IVC and Aorta 
 Immunohistochemistry was done on the IVC and aorta of mice that did not 
undergo IVC ligation. This was done to show increased thrombosis in blood vessels, thus 
a systemic effect of cancer in thrombosis. The NSCLC and colon adenocarcinoma treated 
IVC and aorta were probed for TF against a control nude mouse that did not have a 
xenograft injection. The NSCLC (Figure 11 C and D) showed slightly elevated levels of 
staining along the endothelium of the blood vessels compared to the control mouse 
(Figure 11 A and B). The colon adenocarcinoma (Figure 11 E and F) showed a larger 







Figure 11 Immunohistochemistry of IVC and Aorta with TF. Immunohistochemistry 
was performed on the major blood vessels of the control mice (A and B), the NSCLC (C 
and D), and the colon adenocarcinoma (E and F). There is greater intensity of IVC 




























 This study was able to create an animal model of thrombosis in cancer that 
displayed significantly elevated thrombotic markers in both xenograft tumors and in large 
blood vessels. The mouse model of HT-29 colon adenocarcinoma is the first model of its 
kind. We believe with a larger sample size that the NSCLC will also attain significance, 
as many of our parameters were trending towards significance, such as serum Kyn levels 
at p=0.06. The major findings of the study were the characterization of a new mouse 
model displaying many features of human cancer, and that increased levels of Kyn and 
AHR expression in cancerous mice are correlated with increased thrombosis similar to 
how they are in humans with chronic kidney disease as shown by Shivanna et. al 
(Shivanna 2016). The connection is to be probed for other potential markers in the future 
as well as validating the exact mechanism of the Kyn—AHR pathway.  
Immunohistochemistry of the xenograft tumor showed positive staining for the 
cancer marker and the thrombosis markers. There were some differences in expression of 
the biomarkers. The β-catenin antibody showed positive staining at the cell membrane, 
the cytoplasm, and in the nuclei of both cell lines. This representative of β-catenin, as its 
pathway in Wnt signaling begins at the membrane with the recruitment of the inactivated 
form of β-catenin. Activated β-catenin travels from the membrane to the nucleus where it 
plays a role in cell differentiation and in the mitotic cell cycle (Gammons 2018). AHR, 
conversely, was not found at the membrane. AHR is a cytoplasmic receptor that has a 
wide range of activating ligands. Two of those ligands, IS and Kyn were measured in the 
blood and were found to be both elevated in the serum. This is consistent with the 
	
33 
positive staining for IDO, a rate-limiting enzyme in the production of Kyn, in the blood 
vessels. What we found interesting in the IDO staining was that there was no real staining 
in the tumor. This begs the question if the tumor in this animal model produces IDO or if 
the production is related to tumor growth. The most widely known marker of increased 
thrombosis in this study, TF, showed strong expression in the tumors. This is most likely 
due to its function in angiogenesis, which is required for all tumors that grow beyond 
2mm3  (Arderiu 2014).  
Examination of the tumors was done primarily to demonstrate that the xenograft 
tumor could be a source of these metabolites and proteins, and could explain their 
increase. The hypothesis that a metastatic or in situ xenograft tumor could create a 
hyperthombotic phenotype necessitates testing these markers of thrombosis on vessels in 
the body distant from the tumor site. The validation of increased clot weight and TF in 
IVC endothelium of the colon adenocarcinoma model confirms that the model created a 
hyperthrombotic animal model involving cancer. 
This data is very promising and will be repeated to further evaluate thrombosis in 
cancer. Future studies of this model will attempt to further quantify TF levels in the 
vessel via Western Blot or with image quantification of immunohistochemistry staining. 
Another avenue to explore would be testing for the presence of TF-positive 
microparticles in the blood. This could serve to strengthen the model and give an 
explanation for the mechanism of thrombosis at areas distant from the tumor. The 
microparticles are exocytosed and would therefore have phospholipid membranes of 
similar composition of the cell that released them. Identification of cell-specific TF 
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 Here we developed a novel method of studying thrombosis in colon cancer with 
the HT-29. We probed for characteristics of hyperthrombosis in human patients of cancer 
and chronic kidney disease. Overall, TF, AHR activity, and blood levels of IS and Kyn 
were  significantly elevated in the colon adenocarcinoma, with most of the test 
parameters trending towards significance in the NSCLC model. This is an exciting and 
complex way to study thrombosis in cancer in an in vivo approach, and has many future 
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